• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Emisphere Technologies, Inc. - Product Pipeline Review - Q4 2010 Product Image

Emisphere Technologies, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446309
  • November 2010
  • 49 pages
  • GlobalData

Emisphere Technologies, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Emisphere Technologies, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Emisphere Technologies, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Emisphere Technologies, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Emisphere Technologies, Inc. Snapshot
Emisphere Technologies, Inc. Overview
Key Information
Key Facts
Emisphere Technologies, Inc. – Research and Development Overview
Key Therapeutic Areas
Emisphere Technologies, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Emisphere Technologies, Inc. – Pipeline Products Glance
Emisphere Technologies, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Emisphere Technologies, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Emisphere Technologies, Inc. – Drug Profiles
Oral Heparin
Product Description
Mechanism of Action
R&D Progress
Combined PYY and GLP-1
Product Description
Mechanism of Action
R&D Progress
Oral Acyclovir
Product Description
Mechanism of Action
R&D Progress
Oral Recombinant Parathyroid Hormone
Product Description
Mechanism of Action
R&D Progress
Emisphere Technologies, Inc. – Pipeline Analysis
Emisphere Technologies, Inc. – Pipeline Products by Therapeutic Class
Emisphere Technologies, Inc. Pipeline Products By Target
Emisphere Technologies, Inc. – Pipeline Products by Route of Administration
Emisphere Technologies, Inc. – Pipeline Products by Molecule Type
Emisphere Technologies, Inc. - Dormant Projects
Emisphere Technologies, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Oral Insulin
Emisphere Technologies, Inc. – Company Statement
Emisphere Technologies, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 22, 2010: Emisphere Reports Notification Of Top Level Results On Phase III Study Of Oral Calcitonin In Osteoarthritis Patients
Jul 23, 2010: Emisphere Provides Update On Osteoarthritis Phase III Study With Oral Calcitonin
Jul 17, 2010: Emisphere Technologies Provides Update On High Dose Oral Eligen B12
Apr 15, 2010: Emisphere Partner Initiates Second Phase I Trial Of Oral PTH1-34 For Treatment Of Postmenopausal Osteoporosis
Nov 02, 2009: Interim Study Data Demonstrate Eligen B12 Oral Formulation Achieves Comparable Results to B12 Injection
Nov 02, 2009: Interim Study Data Demonstrate Eligen B12 Oral Formulation Achieves Comparable Results to B12 Injection
Oct 20, 2009: Novel Oral PTH Formulation Using Emisphere's Eligen Technology Showed Potential Therapeutical Advantages To Available Injectable PTH In Postmenopausal Osteoporotic Women
Oct 20, 2009: Novel Oral PTH Formulation Using Emisphere's Eligen Technology Showed Potential Therapeutical Advantages
May 26, 2009: Emisphere Technologies Reports Encouraging Data From Independent Clinical Study Assessing The Effects Of Oral GLP-1 And PYY3-36
Nov 24, 2008: Emisphere Announces Study Results Of New, Orally Bioavailable Formulation Of Parathyroid Hormone ('Pth') Using Eligen Technology
Financial Deals Landscape
Emisphere Technologies, Inc., Deals Volume Summary, 2004 to YTD 2010
Emisphere Technologies, Inc., Deals Summary By Region, 2004 to YTD 2010
Emisphere Technologies, Inc., Deals Summary, 2004 to YTD 2010
Emisphere Technologies, Inc. Detailed Deal Summary
Equity Offering
Emisphere Technologies Completes Registered Direct Offering Of $4 Million
Emisphere Technologies Completes Private Placement Of $4 Million
Emisphere Technologies Completes Private Placement Of $15.74 Million
Licensing Agreements
Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk
Genta Signs Licensing Agreement With Emisphere Technologies
Emisphere Technologies Enters Into Licensing Agreement With Roche
Emisphere Technologies Enters Into Licensing Agreement With Novartis Pharma
Emisphere Technologies Terminates Licensing Agreement With Eli Lilly and Company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS